TMC353121
CAS No. 857066-90-1
TMC353121( —— )
Catalog No. M33522 CAS No. 857066-90-1
TMC353121 is a respiratory syncytial virus (RSV) fusion inhibitor with anti-RSV activity that inhibits the production of the inflammatory cytokines TNF-α, IL-6, and IL-1β, as well as chemokines, KC, IP-10, MCP, and MIP1-α.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTMC353121
-
NoteResearch use only, not for human use.
-
Brief DescriptionTMC353121 is a respiratory syncytial virus (RSV) fusion inhibitor with anti-RSV activity that inhibits the production of the inflammatory cytokines TNF-α, IL-6, and IL-1β, as well as chemokines, KC, IP-10, MCP, and MIP1-α.
-
DescriptionTMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
-
In VitroTMC353121 shows activity against groups A and B RSV and against a panel of clinical isolates with equal potency. TMC353121 is a potent RSV fusion inhibitor in vitro. TMC353121 is active against wild-type RSV (strain LO), with a 50% effective concentration (EC50) of 0.07 ng/mL in HeLaM cells.
-
In VivoAfter i.v. bolus administration of a single dose of 10 mg/kg to Sprague-Dawley rats, the plasma drug concentration-time profile of TMC353121 exhibits multicompartmental pharmacokinetics. Mean plasma drug concentrations decrease rapidly during the first hours after dosing and then more slowly, with a half-life of about 12 h, as determined for the last part of the curve between 8 and 24 h postdose. TMC353121 is rapidly eliminated from plasma (CL=8.6 liters/h/kg) and extensively distributed (Vss=55 liters/kg). TMC353121 is administered once, i.v. at 2.5 mg/kg or at 0.25 mg/kg. Drug levels are determined in lung tissue, serum, and BAL fluid at different time points. TMC353121 followed multicompartment pharmacokinetics, with a fast decay in serum within the first hour after i.v. injection, followed by a slower decay. The drug is eliminated quickly from the blood resulting in very low blood levels after 24 h. Lung concentrations are much higher than serum concentrations and in BAL fluid the drug is just above the limit of detection at 8 h after injection. Very low drug levels can still be detected in the lung 5 days after treatment.
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor | RSV | TNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number857066-90-1
-
Formula Weight558.71
-
Molecular FormulaC32H42N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (89.49 mM; Ultrasonic )
-
SMILESCc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bonfanti JF, et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem. 2008 Feb 28;51(4):875-96.?
molnova catalog
related products
-
CBL0137 hydrochlorid...
CBL0137 activates p53 and inhibits NF-kB (EC50: 0.37/0.47 μM) in the cell-based p53 and NF-kB reporter assays, respectively. It also suppresses histone chaperone FACT.
-
Ganoderic acid C1
Ganoderic acid C1 has anti-inflammatory activity, has potential for treating TNF-α± mediated inflammation in asthma and other inflammatory diseases. Ganoderic acid C1 has anti-tumor-promoting activity. It is moderately active inhibitors against HIV-1 protease.
-
Ordesekimab
Ordesekimab (AMG 714) is a human IgG1 κ-anti-IL-15 (Interleukin Related) monoclonal antibody.
Cart
sales@molnova.com